Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 8/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368236 | 0.90 | OPRL1 (0.48) | PTGER2PTGER3LMNAOPRM1OPRD1 | |
| SCHEMBL13232169 | 0.85 | PTGER2 (0.41) | PTGER2PTGER3LMNA | |
| SCHEMBL10021107 | 0.85 | PTGER2 (0.41) | PTGER2PTGER3 | |
| SCHEMBL317580 | 0.83 | PTGER2 (0.38) | PTGER2PTGER3OPRM1OPRD1OPRK1 | |
| SCHEMBL13313985 | 0.83 | PTGER2 (0.40) | PTGER2PTGER3LMNA | |
| SCHEMBL13232170 | 0.83 | PTGER2 (0.46) | PTGER2PTGER3 | |
| SCHEMBL10021104 | 0.83 | PTGER2 (0.46) | PTGER2PTGER3OPRM1OPRD1OPRK1 | |
| SCHEMBL12981784 | 0.83 | OPRL1 (0.50) | LMNAOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL318512 | 0.82 | PTGER2 (0.41) | PTGER2PTGER3OPRM1OPRD1OPRK1 | |
| SCHEMBL5678158 | 0.77 | LMNA (0.36) | LMNAOPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | claimed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| EP-2285775-B1 | Lactams and their use in the treatment of inter alia ocular hypertension or baldness | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2121672-B1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8420628-B2 | Substituted beta-lactams | ALLERGAN, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420628-B2 | Substituted beta-lactams | ALLERGAN, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2041128-B1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8202855-B2 | Substituted beta-lactams | ALLERGAN, INC (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202855-B2 | Substituted beta-lactams | ALLERGAN, INC (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110275692-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275692-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2008094912-A2 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007146856-A2 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293551-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN | 2007-12-20 | — | — | US | disclosed |
| US-20070293551-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN | 2007-12-20 | — | — | US | disclosed |
| US-20070287742-A1 | Subsitituted Gamma Lactams As Therapeutic Agents | ALLERGAN, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287742-A1 | Subsitituted Gamma Lactams As Therapeutic Agents | ALLERGAN, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007109578-A2 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293551-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | PTGER2 2363/4885PTGER3 2210/4885LMNA 2276/4885 |
| US-20110275692-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | PTGER2 2460/4885PTGER3 2410/4885LMNA 2349/4885 |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | PTGER2 3210/4885PTGER3 2745/4885LMNA 2238/4885 |
| US-20070287742-A1 | Subsitituted Gamma Lactams As Therapeutic Agents | SI, MGAM, GLA | PTGER2 3011/4885PTGER3 2973/4885LMNA 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.